JP2023524684A5 - - Google Patents
Info
- Publication number
- JP2023524684A5 JP2023524684A5 JP2022566065A JP2022566065A JP2023524684A5 JP 2023524684 A5 JP2023524684 A5 JP 2023524684A5 JP 2022566065 A JP2022566065 A JP 2022566065A JP 2022566065 A JP2022566065 A JP 2022566065A JP 2023524684 A5 JP2023524684 A5 JP 2023524684A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- acceptable salt
- pi3kα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024073451A JP2024099776A (ja) | 2020-04-29 | 2024-04-30 | ＰＩ３Ｋα阻害剤およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017571P | 2020-04-29 | 2020-04-29 | |
| US63/017,571 | 2020-04-29 | ||
| US202063066489P | 2020-08-17 | 2020-08-17 | |
| US63/066,489 | 2020-08-17 | ||
| PCT/US2021/029882 WO2021222556A1 (en) | 2020-04-29 | 2021-04-29 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024073451A Division JP2024099776A (ja) | 2020-04-29 | 2024-04-30 | ＰＩ３Ｋα阻害剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524684A JP2023524684A (ja) | 2023-06-13 |
| JP2023524684A5 true JP2023524684A5 (https=) | 2024-05-13 |
| JP7508584B2 JP7508584B2 (ja) | 2024-07-01 |
Family
ID=78373965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566065A Active JP7508584B2 (ja) | 2020-04-29 | 2021-04-29 | ＰＩ３Ｋα阻害剤およびそれらの使用 |
| JP2024073451A Pending JP2024099776A (ja) | 2020-04-29 | 2024-04-30 | ＰＩ３Ｋα阻害剤およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024073451A Pending JP2024099776A (ja) | 2020-04-29 | 2024-04-30 | ＰＩ３Ｋα阻害剤およびそれらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12581252B2 (https=) |
| EP (1) | EP4143196A4 (https=) |
| JP (2) | JP7508584B2 (https=) |
| KR (2) | KR20250057919A (https=) |
| CN (2) | CN116261562A (https=) |
| AU (1) | AU2021263914A1 (https=) |
| BR (1) | BR112022021854A2 (https=) |
| CA (1) | CA3174675A1 (https=) |
| CL (2) | CL2022002985A1 (https=) |
| IL (2) | IL325094A (https=) |
| MX (1) | MX2022013417A (https=) |
| PE (1) | PE20231073A1 (https=) |
| PH (1) | PH12022500017A1 (https=) |
| TW (1) | TW202208354A (https=) |
| WO (1) | WO2021222556A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4143196A4 (en) | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
| WO2022213062A1 (en) * | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| TW202334136A (zh) * | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | PI3Kα抑制劑及其製造與使用方法 |
| CN118302427A (zh) * | 2021-12-02 | 2024-07-05 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
| WO2023114973A1 (en) | 2021-12-17 | 2023-06-22 | Shure Acquisition Holdings, Inc. | Adaptive acoustic echo cancellation for a stereo audio signal |
| WO2023220131A2 (en) * | 2022-05-10 | 2023-11-16 | Relay Therapeutics, Inc. | PI3Kα INHIBITORS AND METHODS OF USE THEREOF |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN116655602B (zh) * | 2022-07-12 | 2025-09-16 | 苏州浦合医药科技有限公司 | PI3Kα变构抑制剂 |
| US20260048045A1 (en) | 2022-08-05 | 2026-02-19 | Scorpion Therapeutics, Inc. | Pi3k-alpha inhibitors for the treatment of cancer |
| US20260041669A1 (en) | 2022-08-11 | 2026-02-12 | Relay Therapeutics, Inc. | Solid forms of a cdk inhibitor |
| JP2025531798A (ja) * | 2022-09-09 | 2025-09-25 | 上海▲瑛▼黎薬業有限公司 | 含窒素複素環化合物、その医薬組成物および使用 |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| TW202541794A (zh) * | 2022-11-02 | 2025-11-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點 |
| JP2025163068A (ja) * | 2022-11-02 | 2025-10-28 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| CN120112533A (zh) * | 2022-11-03 | 2025-06-06 | 上海翰森生物医药科技有限公司 | 多环并环衍生物、其制备方法和应用 |
| WO2024151930A1 (en) * | 2023-01-13 | 2024-07-18 | Relay Therapeutics, Inc. | Pi3k inhibitors and methods of making and using the same |
| WO2024153238A1 (zh) * | 2023-01-20 | 2024-07-25 | 南京再明医药有限公司 | 四环化合物及其应用 |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
| WO2025165834A1 (en) * | 2024-01-31 | 2025-08-07 | Ensem Therapeutics, Inc. | Urea derivatives of tricyclic compounds, and compositions and methods thereof |
| WO2025179441A1 (zh) * | 2024-02-27 | 2025-09-04 | 上海璎黎药业有限公司 | 一种三并环结构化合物、其药物组合物及应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998027975A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
| CA2528938A1 (en) | 2003-06-13 | 2005-02-24 | Zentaris Gmbh | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| EA016945B1 (ru) | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| JP5508027B2 (ja) | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
| WO2009071895A1 (en) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Fused thiazole and thiophene derivatives as kinase inhibitors |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| KR101758046B1 (ko) * | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| JP2013544827A (ja) | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法 |
| CN102140087B (zh) | 2011-01-27 | 2013-02-13 | 清华大学 | 一种色酮类化合物的合成方法 |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| NZ708593A (en) * | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| PE20161323A1 (es) | 2013-09-05 | 2016-11-25 | Hoffmann La Roche | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| EP3400218A4 (en) | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| PT3478679T (pt) * | 2016-07-01 | 2021-06-30 | Pfizer | Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas |
| CN110402248B (zh) * | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| TW201908306A (zh) * | 2017-07-18 | 2019-03-01 | 大陸商南京聖和藥業股份有限公司 | 作為ask抑制劑的雜環化合物及其應用 |
| WO2019103070A1 (ja) | 2017-11-24 | 2019-05-31 | 大日本住友製薬株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| ES3039587T3 (en) | 2017-12-21 | 2025-10-22 | Basf Se | Pesticidal compounds |
| GB201801355D0 (en) | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| WO2020173935A1 (en) | 2019-02-26 | 2020-09-03 | Boehringer Ingelheim International Gmbh | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
| WO2020231990A1 (en) | 2019-05-13 | 2020-11-19 | Relay Therapeutics, Inc. | Fgfr inhibitors and methods of use thereof |
| KR20220044479A (ko) | 2019-06-20 | 2022-04-08 | 유니버시티 오브 켄터키 리서치 파운데이션 | Dcn1/2-매개된 큐린 네딜화의 약학적 활성 피라졸로-피리돈 조절제 |
| EP4143196A4 (en) | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
| EP4267553A1 (en) | 2020-12-24 | 2023-11-01 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
| EP4370124A4 (en) | 2021-07-13 | 2025-05-07 | Relay Therapeutics, Inc. | PI3KA INHIBITORS AND METHODS OF USE THEREOF |
| CN118201896A (zh) | 2021-09-10 | 2024-06-14 | 传达治疗有限公司 | PI3K-α抑制剂和其使用方法 |
| EP4412606A4 (en) | 2021-10-07 | 2025-09-24 | Relay Therapeutics Inc | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF |
| TW202334136A (zh) | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | PI3Kα抑制劑及其製造與使用方法 |
| WO2023081759A1 (en) | 2021-11-03 | 2023-05-11 | Relay Therapeutics, Inc. | Bifunctional pi3k-alpha inhibitors and uses thereof |
| WO2023220131A2 (en) | 2022-05-10 | 2023-11-16 | Relay Therapeutics, Inc. | PI3Kα INHIBITORS AND METHODS OF USE THEREOF |
| WO2024151930A1 (en) | 2023-01-13 | 2024-07-18 | Relay Therapeutics, Inc. | Pi3k inhibitors and methods of making and using the same |
| WO2025106788A1 (en) | 2023-11-15 | 2025-05-22 | Relay Therapeutics, Inc. | PI3Kα INHIBITORS AND METHODS OF MAKING AND USING THE SAME |
-
2021
- 2021-04-29 EP EP21795690.3A patent/EP4143196A4/en active Pending
- 2021-04-29 US US17/921,580 patent/US12581252B2/en active Active
- 2021-04-29 IL IL325094A patent/IL325094A/en unknown
- 2021-04-29 KR KR1020257012192A patent/KR20250057919A/ko active Pending
- 2021-04-29 KR KR1020227041794A patent/KR102797536B1/ko active Active
- 2021-04-29 IL IL297625A patent/IL297625B1/en unknown
- 2021-04-29 WO PCT/US2021/029882 patent/WO2021222556A1/en not_active Ceased
- 2021-04-29 TW TW110115674A patent/TW202208354A/zh unknown
- 2021-04-29 CA CA3174675A patent/CA3174675A1/en active Pending
- 2021-04-29 PE PE2022002518A patent/PE20231073A1/es unknown
- 2021-04-29 AU AU2021263914A patent/AU2021263914A1/en active Pending
- 2021-04-29 JP JP2022566065A patent/JP7508584B2/ja active Active
- 2021-04-29 MX MX2022013417A patent/MX2022013417A/es unknown
- 2021-04-29 BR BR112022021854A patent/BR112022021854A2/pt unknown
- 2021-04-29 CN CN202180043509.2A patent/CN116261562A/zh active Pending
- 2021-04-29 PH PH1/2022/500017A patent/PH12022500017A1/en unknown
- 2021-04-29 CN CN202510407046.3A patent/CN120247911B/zh active Active
-
2022
- 2022-10-27 CL CL2022002985A patent/CL2022002985A1/es unknown
-
2023
- 2023-06-09 US US18/208,023 patent/US12219327B2/en active Active
- 2023-11-30 CL CL2023003583A patent/CL2023003583A1/es unknown
-
2024
- 2024-04-30 JP JP2024073451A patent/JP2024099776A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524684A5 (https=) | ||
| JP2022017295A5 (https=) | ||
| JP2024507938A5 (https=) | ||
| JP2022124458A5 (https=) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2017524735A5 (https=) | ||
| JP2022191257A5 (https=) | ||
| JP2017008088A5 (https=) | ||
| JP2022526850A5 (https=) | ||
| JP2024528127A5 (https=) | ||
| MX2021013711A (es) | Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado. | |
| JP2009514880A5 (https=) | ||
| JP2013056887A5 (https=) | ||
| JP2016501221A5 (https=) | ||
| JP2009514881A5 (https=) | ||
| JP2008521928A5 (https=) | ||
| JP2015512398A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| JP2013544892A5 (https=) | ||
| JP2018516936A5 (https=) | ||
| JP2020536096A5 (https=) | ||
| JP2014512355A5 (https=) | ||
| JP2023548055A5 (https=) | ||
| JP2021535147A5 (https=) |